{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:31Z","timestamp":1791918991933,"version":"4.3.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2020,6,5]]},"DOI":"10.3233\/jhd-190393","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T12:21:26Z","timestamp":1591359686000},"page":"173-184","source":"Crossref","is-referenced-by-count":26,"title":["Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease"],"prefix":"10.1177","volume":"9","author":[{"given":"Andrew","family":"McGarry","sequence":"first","affiliation":[{"name":"Cooper University Health Care at Rowan University, Camden, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics, Herzliya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munish","family":"Mehra","sequence":"additional","affiliation":[{"name":"Tigermed Data Solutions, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor D.","family":"Grachev","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Forrest","family":"Gordon","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha-Matti","family":"Savola","sequence":"additional","affiliation":[{"name":"Teva Pharmaceuticals International GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Papapetropoulos","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Frazer, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hayden","sequence":"additional","affiliation":[{"name":"Prilenia Therapeutics, Herzliya, Israel"},{"name":"CMMT, UBC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JHD-190393_ref1","volume-title":"Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition)","author":"McGarry","year":"2015"},{"key":"10.3233\/JHD-190393_ref2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JHD-190393_ref3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizersACR16 and (-)- OSU6162 display nanomolar affinities at the sigma-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"18","key":"10.3233\/JHD-190393_ref4","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","article-title":"Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses","volume":"232","author":"Sahlholm","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.3233\/JHD-190393_ref5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signalling and cell survival","volume":"3","author":"Hayashi","year":"2007","journal-title":"Cell"},{"issue":"Pt A","key":"10.3233\/JHD-190393_ref6","first-page":"46","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2016","journal-title":"Neurobiol Dis"},{"issue":"18","key":"10.3233\/JHD-190393_ref7","first-page":"3975","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington disease","volume":"25","author":"Geva","year":"2016","journal-title":"Hum Med Gen"},{"key":"10.3233\/JHD-190393_ref8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jphs.2014.12.005","article-title":"Role of sigma-1 receptors in neurodegenerative diseases","volume":"127","author":"Nguyen","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.3233\/JHD-190393_ref9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","article-title":"Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor","volume":"129","author":"Eddings","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JHD-190393_ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1523\/JNEUROSCI.1038-15.2016","article-title":"Enhanced store-operated calcium entry leads to striatal synaptic loss in a Huntington\u2019s disease mouse model","volume":"36","author":"Wu","year":"2016","journal-title":"J Neurosci"},{"issue":"11","key":"10.3233\/JHD-190393_ref11","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J Cell Mol Med"},{"issue":"10","key":"10.3233\/JHD-190393_ref12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo controlled trial of pridopidine in Huntington\u2019s disease","volume":"28","author":"Kieburtz","year":"2013","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-190393_ref13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JHD-170241","article-title":"Safety and exploratory efficacy at 36 months in Open-HART, an open-label extension study of pridopidine in Huntington\u2019s Disease","volume":"6","author":"McGarry","year":"2017","journal-title":"J Huntington Dis"},{"key":"10.3233\/JHD-190393_ref14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"The Unified Huntington\u2019s Disease Rating Scale: Reliability and Consistency","volume":"11","author":"Huntington Study Group (Kieburtz K, primary author)","year":"1996","journal-title":"Mov Dis"},{"issue":"2","key":"10.3233\/JHD-190393_ref15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-190393_ref16","first-page":"17","article-title":"Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken","volume":"54","author":"Fridericia","year":"1921","journal-title":"J Intern Med"},{"issue":"12","key":"10.3233\/JHD-190393_ref17","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s Disease (MermaiHD): A phase 3, randomized, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.3233\/JHD-190393_ref18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE HD): A phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-190393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:51:01Z","timestamp":1777452661000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-190393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":18,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-190393","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}